Compare Dr. Reddys with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AUROBINDO PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AUROBINDO PHARMA DR. REDDYS LAB/
AUROBINDO PHARMA
 
P/E (TTM) x 34.7 16.7 207.4% View Chart
P/BV x 4.7 3.6 131.2% View Chart
Dividend Yield % 0.6 0.3 192.3%  

Financials

 DR. REDDYS LAB   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
AUROBINDO PHARMA
Mar-19
DR. REDDYS LAB/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,363830 405.2%   
Low Rs2,352527 446.2%   
Sales per share (Unadj.) Rs1,054.2333.9 315.7%  
Earnings per share (Unadj.) Rs121.940.4 302.1%  
Cash flow per share (Unadj.) Rs190.251.8 367.5%  
Dividends per share (Unadj.) Rs25.002.50 1,000.0%  
Dividend yield (eoy) %0.90.4 237.5%  
Book value per share (Unadj.) Rs938.7237.1 396.0%  
Shares outstanding (eoy) m166.17585.91 28.4%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.72.0 133.4%   
Avg P/E ratio x23.416.8 139.4%  
P/CF ratio (eoy) x15.013.1 114.6%  
Price / Book Value ratio x3.02.9 106.4%  
Dividend payout %20.56.2 331.0%   
Avg Mkt Cap Rs m474,831397,569 119.4%   
No. of employees `00021.717.9 121.3%   
Total wages/salary Rs m33,80225,849 130.8%   
Avg. sales/employee Rs Th8,091.010,956.9 73.8%   
Avg. wages/employee Rs Th1,561.31,447.7 107.8%   
Avg. net profit/employee Rs Th935.81,324.3 70.7%   
INCOME DATA
Net Sales Rs m175,170195,636 89.5%  
Other income Rs m6,2061,553 399.6%   
Total revenues Rs m181,376197,189 92.0%   
Gross profit Rs m24,42139,519 61.8%  
Depreciation Rs m11,3486,680 169.9%   
Interest Rs m9832,626 37.4%   
Profit before tax Rs m18,29631,767 57.6%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m-1,4037,269 -19.3%   
Profit after tax Rs m20,26023,645 85.7%  
Gross profit margin %13.920.2 69.0%  
Effective tax rate %-7.722.9 -33.5%   
Net profit margin %11.612.1 95.7%  
BALANCE SHEET DATA
Current assets Rs m125,991153,645 82.0%   
Current liabilities Rs m72,141120,429 59.9%   
Net working cap to sales %30.717.0 181.1%  
Current ratio x1.71.3 136.9%  
Inventory Days Days73135 54.1%  
Debtors Days Days10564 164.5%  
Net fixed assets Rs m83,854103,909 80.7%   
Share capital Rs m831586 141.8%   
"Free" reserves Rs m155,157138,322 112.2%   
Net worth Rs m155,988138,908 112.3%   
Long term debt Rs m1,3041,800 72.5%   
Total assets Rs m232,253264,544 87.8%  
Interest coverage x19.613.1 149.7%   
Debt to equity ratio x00 64.5%  
Sales to assets ratio x0.80.7 102.0%   
Return on assets %9.19.9 92.1%  
Return on equity %13.017.0 76.3%  
Return on capital %12.623.8 52.9%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m84,19397,316 86.5%   
Fx outflow Rs m39,61640,589 97.6%   
Net fx Rs m44,57756,727 78.6%   
CASH FLOW
From Operations Rs m29,84116,220 184.0%  
From Investments Rs m-4,923-28,768 17.1%  
From Financial Activity Rs m-25,15919,191 -131.1%  
Net Cashflow Rs m-2666,656 -4.0%  

Share Holding

Indian Promoters % 25.5 54.1 47.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.0 67.9%  
FIIs % 35.3 27.7 127.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.2 150.0%  
Shareholders   75,885 69,601 109.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   NEULAND LABS  WYETH  ABBOTT INDIA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 500 Points; Grasim Industries & HDFC Bank Top Gainers(09:30 am)

Asian share markets are trading on a mixed note tracking a mixed Wall Street session following a big downturn in tech shares.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

Charge Your Portfolio with this Smallcap Proxy Play on India's EV Revolution(Profit Hunter)

Mar 5, 2021

This could be the biggest wealth creator of the decade.

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Mar 9, 2021 10:38 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - PANACEA BIOTECH COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS